Clinical trials: Unspecified Childhood Solid Tumor, Excluding CNS

Unspecified Childhood Solid Tumor, Excluding CNS, Neuroblastoma

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

• Completed
• Age: 12 months to 21 years
• Phase 1

RATIONALE: MLN8237 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of MLN8237 and to see how well it works in…

Trial name

NCT02444884

Testing

MLN8237

Volunteers

54 people

Sponsor

Children's Oncology Group